These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 17890884)

  • 1. An alternative therapy for patients with hepatic impairment?
    Choo SP; Venook AP
    Onkologie; 2007 Oct; 30(10):474-5. PubMed ID: 17890884
    [No Abstract]   [Full Text] [Related]  

  • 2. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia.
    Moosmann N; Laessig D; Michaely HJ; Schulz C; Heinemann V
    Onkologie; 2007 Oct; 30(10):509-12. PubMed ID: 17890890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Systemic therapy for colorectal cancer].
    Pestalozzi BC; Jäger D; Knuth A
    Chirurg; 2005 Jun; 76(6):570-2, 574. PubMed ID: 15905968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic toxicities associated with the use of preoperative systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver.
    Cleary JM; Tanabe KT; Lauwers GY; Zhu AX
    Oncologist; 2009 Nov; 14(11):1095-105. PubMed ID: 19880627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting.
    Asseburg C; Frank M; Köhne CH; Hartmann JT; Griebsch I; Mohr A; Osowski U; Schulten J; Mittendorf T
    Clin Ther; 2011 Apr; 33(4):482-97. PubMed ID: 21635994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aneurysm formation in an angiomyolipoma during bevacizumab combination therapy.
    Maleux G; Vaninbroukx J; Heye S; van Cutsem E; Oyen R
    Acta Oncol; 2010 Aug; 49(6):864-6. PubMed ID: 20230212
    [No Abstract]   [Full Text] [Related]  

  • 7. Consequences of chemotherapy on resection of colorectal liver metastases.
    Pessaux P; Chenard MP; Bachellier P; Jaeck D
    J Visc Surg; 2010 Aug; 147(4):e193-201. PubMed ID: 20655821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in combination with cetuximab and irinotecan after failure of cetuximab and irinotecan in patients with metastatic colorectal cancer.
    Larsen FO; Pfeiffer P; Nielsen D; Skougaard K; Qvortrup C; Vistisen K; Fromm AL; Jørgensen TL; Bjerregaard JK; Hoegdall E; Jensen BV
    Acta Oncol; 2011 May; 50(4):574-7. PubMed ID: 21529301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response.
    Gotlib V; Khaled S; Lapko I; Mar N; Saif MW
    Anticancer Drugs; 2006 Nov; 17(10):1227-9. PubMed ID: 17075324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cetuximab and chemotherapy for patients with unresectable CRC liver metastasis: are we changing the natural course of the disease?
    Ramos FJ; Tabernero J
    Onkologie; 2007 Dec; 30(12):602-4. PubMed ID: 18063871
    [No Abstract]   [Full Text] [Related]  

  • 11. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases.
    Ribero D; Wang H; Donadon M; Zorzi D; Thomas MB; Eng C; Chang DZ; Curley SA; Abdalla EK; Ellis LM; Vauthey JN
    Cancer; 2007 Dec; 110(12):2761-7. PubMed ID: 17960603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in metastatic colorectal cancer.
    Broadbridge VT; Karapetis CS; Price TJ
    Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
    Malik Z; Eng C
    Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
    [No Abstract]   [Full Text] [Related]  

  • 14. Perforating dermatosis in a patient receiving bevacizumab.
    Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
    J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
    [No Abstract]   [Full Text] [Related]  

  • 15. Highlights from: the 2009 American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA; January 15-17, 2009.
    Quill T
    Clin Colorectal Cancer; 2009 Apr; 8(2):72-6. PubMed ID: 19736659
    [No Abstract]   [Full Text] [Related]  

  • 16. Oncological management of unresectable liver metastases.
    Prenen H; Van Cutsem E
    Dig Dis; 2012; 30 Suppl 2():137-42. PubMed ID: 23207946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful and well-tolerated second line therapy with cetuximab, irinotecan, and raltitrexed in progressive liver disease due to metastatic colon cancer.
    Geurs F; Vandewaeter S; Ponette S; Ponette J; Knape S; Demetter P
    J Gastrointest Cancer; 2008; 39(1-4):26-8. PubMed ID: 19418267
    [No Abstract]   [Full Text] [Related]  

  • 18. Reversible tumor growth acceleration following bevacizumab interruption in metastatic colorectal cancer patients scheduled for surgery.
    Cacheux W; Boisserie T; Staudacher L; Vignaux O; Dousset B; Soubrane O; Terris B; Mateus C; Chaussade S; Goldwasser F
    Ann Oncol; 2008 Sep; 19(9):1659-61. PubMed ID: 18684697
    [No Abstract]   [Full Text] [Related]  

  • 19. Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab.
    Cercek A; D'Angelica M; Power D; Capanu M; Gewirtz A; Patel D; Allen P; Fong Y; DeMatteo RP; Jarnagin WR; Kemeny NE
    Ann Surg Oncol; 2014 Feb; 21(2):479-86. PubMed ID: 24154839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Common side effects and interactions of colorectal cancer therapeutic agents.
    Holt K
    J Pract Nurs; 2011; 61(1):7-20. PubMed ID: 21751717
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.